188 related articles for article (PubMed ID: 36958527)
1. The complex molecular pharmacology of the dopamine D
Ferraiolo M; Hermans E
Pharmacol Ther; 2023 May; 245():108392. PubMed ID: 36958527
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D
Ferraiolo M; Atik H; Ponthot R; Koener B; Hanson J; Hermans E
Neuropharmacology; 2022 Apr; 207():108942. PubMed ID: 35026287
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
4. [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].
Tadori Y; Kobayashi H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Nov; 34(5-6):127-32. PubMed ID: 25536763
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole and pramipexole, the new agonists.
Hobson DE; Pourcher E; Martin WR
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
[TBL] [Abstract][Full Text] [Related]
6. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K; Lyons KE
Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
[TBL] [Abstract][Full Text] [Related]
7. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.
Wood M; Dubois V; Scheller D; Gillard M
Br J Pharmacol; 2015 Feb; 172(4):1124-35. PubMed ID: 25339241
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Seeman P
Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
[TBL] [Abstract][Full Text] [Related]
10. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
11. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
Fenu S; Espa E; Pisanu A; Di Chiara G
Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
[TBL] [Abstract][Full Text] [Related]
12. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic agonists in Parkinson's disease.
Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC
Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302
[TBL] [Abstract][Full Text] [Related]
15. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
17. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.
Sun Y; van Valkenhoef G; Morel T
Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588
[TBL] [Abstract][Full Text] [Related]
18. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
Rascol O
J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
[TBL] [Abstract][Full Text] [Related]
19. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Taguchi S; Koide H; Oiwa H; Hayashi M; Ogawa K; Ito C; Nakashima K; Yuasa T; Yasumoto A; Ando H; Fujikake A; Fukuoka T; Tokui K; Izumi M; Tsunoda Y; Kawagashira Y; Okada Y; Niwa JI; Doyu M
PLoS One; 2021; 16(7):e0255274. PubMed ID: 34320022
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis.
Chen XT; Zhang Q; Wen SY; Chen FF; Zhou CQ
Eur J Neurol; 2023 Mar; 30(3):762-773. PubMed ID: 36380711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
